BETTICA Paolo

Paolo Bettica is an Italian physician with a PhD in Pharmacology and Toxicology and a specialization in Clinical Pharmacology. After more than 10 years in academia and hospital, he started working in Pharmaceutical companies with increasing responsibilities. Currently he is the Chief Medical Officer and Vice president Drug Development of the Italfarmaco Group.
Leading the Drug Development of Italfarmaco he is responsible for the development of the pipeline of NCEs and NMEs up to market and post-approval in different therapeutic areas such as Rare Diseases, Oncology, Muscle and Neuro Degeneration, Cardiovascular.
In his 25+ years in Pharma Paolo has worked in all phases of Drug Development from early development up to post-approval phases in different therapeutic areas such as Neuroscience, Pain, Rheumatology, Endocrinology, Oncology, Rare Diseases. During this time, he led the teams that registered Duvyzat (the first non-steroidal treatment for Duchenne Muscular Dystrophy), Teglutik/Tiglutik (the first oral suspension of riluzole for Amyotrophic Lateral Sclerosis), and Ghemaxane (an enoxaparin biosimilar).